- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Amgen Inc (AMGN)
View the Amgen Inc stock price live, this page displays NASDAQ AMGN stock exchange data. View the AMGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Amgen Inc real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AMGN quote. (ISIN: US0311621009)
What Is the Current Stock Price of Amgen?
The Amgen Inc stock price is 280.78.
Who Founded Amgen?
Amgen was founded in 1980 by venture capitalist William K. Bowes Jr. The company was originally named Applied Molecular Genetics (which was later shortened to Amgen).
Where is Amgen HQ?
While this company has operations around the globe, the current AMGN headquarters is located in Thousand Oaks, California (U.S.).
When Did Amgen Stock Go Public?
Amgen went public on June 17, 1983. It was among the earliest biotechnology companies to be listed on the NASDAQ.
When Was the Last Time Amgen Stock Split?
Amgen's most recent stock split occurred on November 21, 1999. This was a 2-for-1 stock split. The company has had four 2-for-1 splits in its history (1987, 1991, 1995, and 1999).
What Stock Exchange Does Amgen Trade On?
Amgen Inc is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Amgen?
The stock symbol for Amgen Inc is "AMGN."
Is AMGN the Same as $AMGN?
$AMGN is a common way to refer to the Amgen Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol.
What Are Amgen's Key Therapeutic Areas?
Amgen focuses on several key therapeutic areas including oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. The company specializes in biotechnology medicines derived from living cells.
What Are Amgen's Major Products?
Amgen's portfolio includes blockbuster drugs such as Enbrel (for rheumatoid arthritis), Prolia and XGEVA (for osteoporosis and bone health), Repatha (for cholesterol management), Otezla (for psoriasis), Neulasta and Neupogen (for patients undergoing chemotherapy), and KYPROLIS (for multiple myeloma).
What Recent Acquisitions Has Amgen Made?
Amgen completed the acquisition of Horizon Therapeutics in October 2023 for approximately $27.8 billion, one of its largest acquisitions. Other notable acquisitions include Onyx Pharmaceuticals (2013), Five Prime Therapeutics (2021), and ChemoCentryx (2022).
Is Amgen a Good Stock to Buy?
Determining whether Amgen, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
What Is the Current Stock Price of Amgen?
The Amgen Inc stock price is 280.78.
Who Founded Amgen?
Amgen was founded in 1980 by venture capitalist William K. Bowes Jr. The company was originally named Applied Molecular Genetics (which was later shortened to Amgen).
Where is Amgen HQ?
While this company has operations around the globe, the current AMGN headquarters is located in Thousand Oaks, California (U.S.).
When Did Amgen Stock Go Public?
Amgen went public on June 17, 1983. It was among the earliest biotechnology companies to be listed on the NASDAQ.
When Was the Last Time Amgen Stock Split?
Amgen's most recent stock split occurred on November 21, 1999. This was a 2-for-1 stock split. The company has had four 2-for-1 splits in its history (1987, 1991, 1995, and 1999).
What Stock Exchange Does Amgen Trade On?
Amgen Inc is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Amgen?
The stock symbol for Amgen Inc is "AMGN."
Is AMGN the Same as $AMGN?
$AMGN is a common way to refer to the Amgen Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol.
What Are Amgen's Key Therapeutic Areas?
Amgen focuses on several key therapeutic areas including oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. The company specializes in biotechnology medicines derived from living cells.
What Are Amgen's Major Products?
Amgen's portfolio includes blockbuster drugs such as Enbrel (for rheumatoid arthritis), Prolia and XGEVA (for osteoporosis and bone health), Repatha (for cholesterol management), Otezla (for psoriasis), Neulasta and Neupogen (for patients undergoing chemotherapy), and KYPROLIS (for multiple myeloma).
What Recent Acquisitions Has Amgen Made?
Amgen completed the acquisition of Horizon Therapeutics in October 2023 for approximately $27.8 billion, one of its largest acquisitions. Other notable acquisitions include Onyx Pharmaceuticals (2013), Five Prime Therapeutics (2021), and ChemoCentryx (2022).
Is Amgen a Good Stock to Buy?
Determining whether Amgen, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
280.55
+2.65(+0.95%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
274.42
282.26
52 wk Range
253.30
346.85
AMGN Scorecard
Full Analysis
High shareholder yield
Earnings results expected in 7 days
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
274.42282.26
52 wk Range
253.30346.85
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.43%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.43%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AMGN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
316.23
Upside
+12.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 14 consecutive years
Amgen Inc Company Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Amgen Inc SWOT Analysis
Analyst Optimism | Discover why analysts maintain bullish outlooks, with price targets ranging from $315 to $362, reflecting confidence in Amgen's diverse portfolio and future prospects |
Market Opportunity | Delve into Amgen's strategic focus on the lucrative obesity treatment market, with MariTide potentially worth $140 per share based on discounted cash flow analysis |
Financial Fortitude | Explore Amgen's impressive financial performance, with revenue growth of 18.6% and a 14-year streak of dividend increases, showcasing its stability and potential |
Biotech Powerhouse | Amgen's robust product portfolio and pipeline, including potential obesity treatment MariTide, position it for significant growth in the competitive biopharmaceutical landscape |
Amgen Inc Earnings Call Summary for Q3/2024
- Q3 revenues up 23% to $8.5B; ten products with double-digit growth in oncology and rare diseases
- Rare disease portfolio generated $1.2B; TEPEZZA led with $488M
- MariTide for obesity and type 2 diabetes advancing to Phase III trials
- 2024 revenue forecast: $33.0B-$33.8B; Non-GAAP EPS expected $19.20-$20
- Increased R&D and manufacturing investments, particularly for MariTide and late-stage pipeline
Last Updated: 10/31/2024, 12:34 PM
Read Full TranscriptCompare AMGN to Peers and Sector
Metrics to compare | AMGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAMGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 36.9x | −2.9x | −0.5x | |
PEG Ratio | −0.92 | −0.01 | 0.00 | |
Price / Book | 25.7x | 1.6x | 2.6x | |
Price / LTM Sales | 4.5x | 3.2x | 2.9x | |
Upside (Analyst Target) | 16.0% | 36.2% | 57.2% | |
Fair Value Upside | Unlock | 16.0% | 8.9% | Unlock |
Analyst Ratings
14 Buy
15 Hold
3 Sell
Ratings:
32 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 316.23
(+12.72% Upside)
Earnings
Latest Release
Feb 04, 2025
EPS / Forecast
5.31 / 5.04
Revenue / Forecast
9.10B / 8.85B
People Also Watch
FAQ
What Is the Amgen (AMGN) Stock Price Today?
The Amgen stock price today is 280.55
What Stock Exchange Does Amgen Trade On?
Amgen is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Amgen?
The stock symbol for Amgen is "AMGN."
Does Amgen Pay Dividends? What’s The Current Dividend Yield?
The Amgen dividend yield is 3.43%.
What Is the Amgen Market Cap?
As of today, Amgen market cap is 151.28B.
What is Amgen Earnings Per Share?
The Amgen EPS is 7.62.
What Is the Next Amgen Earnings Date?
Amgen will release its next earnings report on May 01, 2025.
From a Technical Analysis Perspective, Is AMGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.